Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration. Schneider M, Bjerager J, Hodzic-Hadzibegovic D, Klefter ON, et al. Graefes Arch Clin Exp Ophthalmol 2024 Feb 28. doi: 10.1007/s00417-024-06421.

Read + Share

Amedeo Smart

Independent Medical Education

Schneider M, Bjerager J, Hodzic-Hadzibegovic D, Klefter ON, et al. Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2024 Feb 28. doi: 10.1007/s00417-024-06421.
PMID: 38416237